Cited by 1,867Virus-based gene therapy researchImmunodeficiency and Autoimmune DisordersCAR-T cell therapy research

The DOI matches its Crossref record.

A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency

Hacein-Bey-Abina, Salima, von Kalle, Christof, Schmidt, Manfred, Le Deist, Françoise, Wulffraat, Nicolas, McIntyre, Elisabeth, Radford, Isabelle, Villeval, Jean-Luc, Fraser, Christopher C., Cavazzana-Calvo, Marina, Fischer, Alain·2003·New England Journal of Medicine

DOI 10.1056/nejm200301163480314

Open this paper in CoChat — free account

Abstract

To the Editor: We recently reported (April 18 issue)1 the sustained correction of X-linked severe combined immunodeficiency disease by ex vivo, retrovirally mediated transfer of the γc gene into CD34+ cells in four of five patients with the disease. These results have since been confirmed in four additional patients with typical X-linked severe combined immunodeficiency. Of the first four successfully treated patients, three continue to do well up to 3.6 years after gene therapy, whereas a serious adverse event occurred in the fourth patient. At a routine checkup 30 months after gene therapy, lymphocytosis consisting of a monoclonal population . . .

Integrity signals

Registry

Crossref · 10.1056/nejm200301163480314

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

No references could be resolved yet.

Research works printed but not linked: 5

10.1056/NEJMoa012616 · DOI
10.1182/blood-2002-02-0407 · DOI
Rabbitts TH, 1999, Cancer Res, 59, 1794s
10.3109/08977199309011023 · DOI
10.1056/NEJM199902183400703 · DOI

Sorted by citations

Items 101–200 of 1,003

Delivery of RNA Interference
Li, C. X., Parker, A. E., Menocal, E. M., Xiang, S., Borodyansky, L., & Fruehauf, J. H. (2006) · Cell Cycle · doi:10.4161/cc.5.18.3192 · Cited by 191
Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells
Zhang, F., Thornhill, S., Howe, S., Ulaganathan, M., Schambach, A., Sinclair, J., Kinnon, C., Gaspar, H. B., Antoniou, M., & Thrasher, A. (2007) · Blood · doi:10.1182/blood-2006-12-060814 · Cited by 191
Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy.
Wang, Y.-H., Su, H.-H., Yang, Y., Hu, Y.-X., Zhang, L., Blancafort, P., & Huang, L. (2013) · Molecular Therapy · doi:10.1038/mt.2012.250 · Cited by 189
Regeneration Next: Toward Heart Stem Cell Therapeutics
Hansson, E. M., Lindsay, M. E., & Chien, K. R. (2009) · Cell stem cell · doi:10.1016/j.stem.2009.09.004 · Cited by 168
Gene Electrotransfer: A Mechanistic Perspective
Rosazza, C., Meglič, S. H., Zumbusch, A., Rols, M., & Miklavčič, D. (2016) · Current Gene Therapy · doi:10.2174/1566523216666160331130040 · Cited by 228
“Nevertheless, insertional mutagenesis or excessive immune response of the host can render this method unsafe [5-8].”
Background
Liver disease associated with canalicular transport defects: Current and future therapies
Stapelbroek, J. M., van Erpecum, K. J., Klomp, L. W. J., & Houwen, R. H. J. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.11.012 · Cited by 180
“Some of the early trials in humans resulted in mortality and enthusiasm for this approach decreased [180].”
Background
Evaluating the state of the science for adeno-associated virus integration: An integrated perspective
Sabatino, D. E., Bushman, F. D., Chandler, R. J., Crystal, R. G., Davidson, B. L., Dolmetsch, R. E., Eggan, K. C., Gao, G., Gil-Fariña, I., Kay, M. A., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.06.004 · Cited by 222
Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population.
Kustikova, O., Wahlers, A., Kühlcke, K., Stahle, B., Zander, A., Baum, C., & Fehse, B. (2003) · Blood · doi:10.1182/blood-2003-05-1424 · Cited by 185
Safety of retroviral gene marking with a truncated NGF receptor
Bonini, C., Grez, M., Traversari, C., Ciceri, F., Marktel, S., Ferrari, G., Dinauer, M., Sadat, M. A., Aiuti, A., Deola, S., et al. (2003) · Nature Medicine · doi:10.1038/nm0403-367 · Cited by 182
Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.
Kang, E., Choi, U., Theobald, N., Linton, G., Priel, D. L. L., Kuhns, D., & Malech, H. (2010) · Blood · doi:10.1182/blood-2009-05-222760 · Cited by 181
Trial Watch:
Pol, J. G., Bloy, N., Obrist, F., Eggermont, A. M. M., Galon, J., Cremer, I., Erbs, P., Limacher, J., Préville, X., Zitvogel, L., et al. (2014) · OncoImmunology · doi:10.4161/onci.28694 · Cited by 94
“These include (but may be not limited to): (1) the heterogeneous and relatively incomplete diffusion of oncolytic viruses within neoplastic lesions;(117-127) (2) the equilibrium that is generally established between oncolytic viruses and continuously proliferating, non-infected cancer cells, which eventually shifts in…”
Recombinant Adeno-Associated Viral Integration and Genotoxicity: Insights from Animal Models
Chandler, R. J., Sands, M. S., & Venditti, C. P. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.009 · Cited by 211
“However, after two highly publicized deaths occurring in two separate gene therapy clinical trials in the late 1990s and early 2000s, the future of gene therapy appeared bleak.(4,5) The toxicity observed in these clinical trials was caused by immunogenicity to an adenoviral vector and then to insertional mutagenesis b…”
Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing
Paruzynski, A., Arens, A., Gabriel, R., Bartholomae, C. C., Scholz, S., Wang, W., Wolf, S., Glimm, H., Schmidt, M., & Kalle, C. V. (2010) · Nature Protocols · doi:10.1038/nprot.2010.87 · Cited by 180
“However, gene therapy with oncoretroviral vectors has caused insertional activation of proto-oncogenes and uncontrolled clonal proliferation in several subjects with X-linked severe combined immunodeficiency and X-linked chronic granulomatous diseas”
BackgroundSelf-citation
Lentiviral delivery of short hairpin RNAs
Manjunath, N., Wu, H., Subramanya, S., & Shankar, P. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.004 · Cited by 170
Human T-Cell Leukemia Virus Type 1 Integration Target Sites in the Human Genome: Comparison with Those of Other Retroviruses
Derse, D., Crise, B. J., Li, Y., Princler, G. L., Lum, N., Stewart, C., McGrath, C. F., Hughes, S. H., Munroe, D. J., & Wu, X. (2007) · Journal of Virology · doi:10.1128/jvi.02752-06 · Cited by 180
“The risk of insertional mutagenesis by retroviral vectors is exemplified by the development of leukemia from vector DNA insertion in the X-SCID gene therapy trial (9, 22, 23).”
Background
Durable and efficient gene silencing in vivo by hit-and-run epigenome editing
Cappelluti, M. A., Poeta, V. M., Valsoni, S., Quarato, P., Merlin, S., Merelli, I., & Lombardo, A. (2024) · Nature · doi:10.1038/s41586-024-07087-8 · Cited by 207
“This approach poses safety concerns for clinical translation, as inserting vectors into the host genome can lead to mutagenesis 17,18 whereas prolonged expression of editors could promote their off-targeting activity, as previously shown 19 for CRISPR–Cas9.”
Background
Mesenchymal stem cells: A promising targeted-delivery vehicle in cancer gene therapy
Hu, Y., Ying-hua, F., Tabata, Y., & Gao, J. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.05.015 · Cited by 185
A subset of mouse tracheal epithelial basal cells generates large colonies in vitro.
Schoch, K., Lori, A., Burns, K., Eldred, T., Olsen, J., & Randell, S. (2004) · American Journal of Physiology - Lung cellular and Molecular Physiology · doi:10.1152/ajplung.00112.2003 · Cited by 174
“Alternatively, if integrating vectors put cells at risk for insertional mutagenesis (7, 15), and stem cells in the airway are more sensitive to malignant transformation, then transfection of airway columnar cells may be less dangerous.”
Background
Clinical strategies for expansion of haematopoietic stem cells
Sorrentino, B. P. (2004) · Nature reviews. Immunology · doi:10.1038/nri1487 · Cited by 154
“However, in the case of X-linked SCID (XSCID), two patients have developed T-cell leukaemia as a result of insertional mutagenesis from the gene-therapy vecto”
Background
Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor
Leen, A. M., Sukumaran, S., Watanabe, N., Mohammed, S., Keirnan, J. M., Yanagisawa, R., Anurathapan, U., Rendon, D. A., Heslop, H. E., Rooney, C. M., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.47 · Cited by 183
New multivalent cationic lipids reveal bell curve for transfection efficiency versus membrane charge density: lipid–DNA complexes for gene delivery
Ahmad, A. K., Evans, H. M., Ewert, K. K., George, C. X., Samuel, C. E., & Safinya, C. R. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.717 · Cited by 182
“Recent setbacks in clinical trials with viral vectors, in particular a fatality induced by a severe inflammatory response [4] and insertional mutagenesis caused by retroviral vectors [5], have further promoted a diligent effort in developing efficient nonviral methods.”
Background
Occurrence of leukaemia following gene therapy of X-linked SCID
Kohn, D. B., Sadelain, M., & Glorioso, J. C. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1122 · Cited by 340
“The text and reference should have been: See also Refs 14, 18 an”
Background
Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling
Brown, V. I., Fang, J.-J., Alcorn, K., Barr, R., Kim, J. M., Wasserman, R., & Grupp, S. (2003) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.2436348100 · Cited by 168
Lentiviral vectors: are they the future of animal transgenesis?
Park, F. (2007) · Physiological Genomics · doi:10.1152/physiolgenomics.00069.2007 · Cited by 167
“In light of recent gene therapy studies documenting leukomogenesis in young children treated with retroviral-manipulated hematopoietic stem cells (37, 38), the method of lentiviral transgenesis may have an alternate use as a preclinical model Review”
BackgroundMethod
Gammaretroviral Vectors: Biology, Technology and Application
Maetzig, T., Galla, M., Baum, C., & Schambach, A. (2011) · Viruses · doi:10.3390/v3060677 · Cited by 161
Nucleofection Is an Efficient Nonviral Transfection Technique for Human Bone Marrow–Derived Mesenchymal Stem Cells
Aluigi, M., Fogli, M., Curti, A., Isidori, A., Gruppioni, E., Chiodoni, C., Colombo, M., Versura, P., D'Errico-Grigioni, A., Ferri, E., et al. (2006) · Stem Cells · doi:10.1634/stemcells.2005-0198 · Cited by 166
Custom zinc-finger nucleases for use in human cells
Alwin, S., Gere, M. B., Guhl, E., Effertz, K., Barbas, C. F., Segal, D. J., Weitzman, M. D., & Cathomen, T. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.06.094 · Cited by 165
“Moreover, random integration can have genotoxic side effects by disrupting cellular genes or by misregulating expression of nearby genes, as recently shown in a gene therapy trial involving randomly integrating retroviral vectors [1–4].”
Background
Combinatorial Gene Therapy Accelerates Bone Regeneration: Non‐Viral Dual Delivery of VEGF and BMP2 in a Collagen‐Nanohydroxyapatite Scaffold
Curtin, C., Tierney, E. G., McSorley, K., Cryan, S., Duffy, G., & O'Brien, F. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201400397 · Cited by 165
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.
Quintarelli, C., Vera, J., Savoldo, B., Giordano-Attianese, G., Pule, M., Foster, A., Heslop, H., Rooney, C., Brenner, M., & Dotti, G. (2007) · Blood · doi:10.1182/blood-2007-02-072843 · Cited by 164
Large animal models and gene therapy
Casal, M. L., & Haskins, M. (2006) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201535 · Cited by 164
Supernatural T cells: genetic modification of T cells for cancer therapy
Kershaw, M. H., Teng, M. W. L., Smyth, M. J., & Darcy, P. K. (2005) · Nature reviews. Immunology · doi:10.1038/nri1729 · Cited by 150
“So far, leukaemias have been documented to arise in humans from haematopoietic stem cells that have been modified with the gene that encodes the common cytokine-receptor γ-chain (γ c”
Background
Self-inactivating Gammaretroviral Vectors for Gene Therapy of X-linked Severe Combined Immunodeficiency
Thornhill, S., Schambach, A., Howe, S., Ulaganathan, M., Grassman, E., Williams, D. A., Schiedlmeier, B., Sebire, N. J., Gaspar, H. B., Kinnon, C., et al. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300393 · Cited by 163
Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs
Girard-Gagnepain, A., Amirache, F., Costa, C., Lévy, C., Frecha, C. A., Fusil, F., Négre, D., Lavillette, D., Cosset, F., & Verhoeyen, E. (2014) · Blood · doi:10.1182/blood-2014-02-558163 · Cited by 195
Chitosan for Gene Delivery and Orthopedic Tissue Engineering Applications
Raftery, R. M., O’Brien, F. J., & Cryan, S. (2013) · Molecules · doi:10.3390/molecules18055611 · Cited by 180
“concerns and difficult manufacturing processes, the risk of toxicity and immunogenicity [35] and, most significantly, with integrating retroviral-based vectors, the possibility of insertional mutagenesis [36].”
Background
Analysis of Lentiviral Vector Integration in HIV+ Study Subjects Receiving Autologous Infusions of Gene Modified CD4+ T Cells
Wang, G. P., Levine, B. L., Binder, G. K., Berry, C. C., Malani, N., McGarrity, G., Tebas, P., June, C. H., & Bushman, F. D. (2009) · Molecular Therapy · doi:10.1038/mt.2009.16 · Cited by 147
High-throughput 5’ UTR engineering for enhanced protein production in non-viral gene therapies
Cao, J., Novoa, E. M., Zhang, Z., Chen, W. C. W., Liu, D., Choi, G. C. G., Wong, A. S. L., Wehrspaun, C., Kellis, M., & Lu, T. K. (2021) · Nature Communications · doi:10.1038/s41467-021-24436-7 · Cited by 159
Strategies to Optimize Adult Stem Cell Therapy for Tissue Regeneration
Liu, S., Zhou, J., Zhang, X., Liu, Y., Chen, J., Hu, B., Song, J., & Zhang, Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060982 · Cited by 177
“One of the effective and controllable methods to apply growth factors that can augment stem cell treatments is genetic manipulation of the cells overexpressing diverse growth factors before implantation [57,58].”
Current Advances in Retroviral Gene Therapy
Yi, Y., Noh, M. J., & Lee, K. H. (2011) · Current Gene Therapy · doi:10.2174/156652311795684740 · Cited by 145
Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice
Chu, Y., Hochberg, J. C., Yahr, A., Ayello, J. S., van de Ven, C., Barth, M. J., Czuczman, M. S., & Cairo, M. S. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0114 · Cited by 177
“Gene-engineered T cells with viral methods have been used for cancer therapy with success, but concerns about safety has arisen after X-SCID patients developed cancerous T cells after receiving hematopoietic stem cells transduced with recombinant retrovirus (38), and manufacturing challenges may also hamper clinical p…”
Background
Genetics and immunopathology of chronic granulomatous disease
Stasia, M. J., & Li, X. J. (2008) · Seminars in Immunopathology · doi:10.1007/s00281-008-0121-8 · Cited by 159
Site-directed transposon integration in human cells
Yant, S., Huang, Y., Akache, B., & Kay, M. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm089 · Cited by 155
Gene therapy: X-SCID transgene leukaemogenicity
Thrasher, A., Gaspar, H. B., Baum, C., Modlich, U., Schambach, A., Candotti, F., Otsu, M., Sorrentino, B., Scobie, L., Cameron, E., et al. (2006) · Nature · doi:10.1038/nature05219 · Cited by 155
Self-citation
Primary Immunodeficiency Diseases
Hernandez-Trujillo, V. P., Scalchunes, C., Hernandez-Trujillo, H. S., Boyle, J. M., Williams, P. V., Boyle, M., & Orange, J. S. (2015) · Clinical Pediatrics · doi:10.1177/0009922815574079 · Cited by 22
Efficient in vitro and in vivo pulmonary delivery of nucleic acid by carbon dot-based nanocarriers
Pierrat, P., Wang, R., Kereselidze, D., Lux, M., Didier, P., Kichler, A., Pons, F., & Lebeau, L. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.02.017 · Cited by 182
“Though viral vectors offer greater efficiency of gene delivery, fundamental problems are associated with these carriers and many clinical trials in which they were used have been interrupted because of unexpected adverse effects [1-4].”
Background
Retroviral DNA Integration
Lesbats, P., Engelman, A., & Cherepanov, P. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00125 · Cited by 250
American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells.
Kohn, D., Sadelain, M., Dunbar, C., Bodine, D., Kiem, H., Candotti, F., Tisdale, J., Rivière, I., Blau, C. A., Richard, R. E., et al. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00212-0 · Cited by 150
“Tragically, two subjects of the French trial for XSCID developed T-cell leukemia more than 2 years after the gene transfer procedure [6].”
Background
Water-soluble carbosilane dendrimers: synthesis biocompatibility and complexation with oligonucleotides; evaluation for medical applications.
Bermejo, J. F., Ortega, P., Chonco, L., Eritja, R., Samaniego, R., Müllner, M., de Jesús, E., de la Mata, F. J., Flores, J. C., Gómez, R., et al. (2007) · Chemistry · doi:10.1002/chem.200600594 · Cited by 148
Precise hit: adeno-associated virus in gene targeting
Vasileva, A., & Jessberger, R. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1266 · Cited by 135
“Human gene-therapy trials using retroviral vectors indicate that quasi-random integration of transgenes can indeed induce malignant transformation in transduced cell”
Background
Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation.
Mostoslavsky, G., Kotton, D. N., Fabian, A., Gray, J., Lee, J.-S., & Mulligan, R. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.01.005 · Cited by 147
“The studies reported here were motivated in large part by recent reports by Fischer and co-workers, which described the development of leukemia-like syndromes in severe combined immunodeficiency disease (SCID) patients transplanted with cells transduced by oncoretroviral vectors [19–23].”
Result
The LMO2 T-Cell Oncogene Is Activated via Chromosomal Translocations or Retroviral Insertion during Gene Therapy but Has No Mandatory Role in Normal T-Cell Development
McCormack, M., Forster, A., Drynan, L., Pannell, R., & Rabbitts, T. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.24.9003-9013.2003 · Cited by 146
“The recent development of leukemia by LMO2 activation via retroviral insertion in two X-SCID gene therapy patients (9a) has reinforced this T-cell tropism, as both patients developed T-cell acute leukemias (9).”
Background
Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency
Prieve, M. G., Harvie, P., Monahan, S. D., Roy, D., Li, A. G., Blevins, T. L., Paschal, A. E., Waldheim, M., Bell, E. C., Galperin, A., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.024 · Cited by 145
Primed 3D injectable microniches enabling low-dosage cell therapy for critical limb ischemia
Li, Y., Liu, W., Liu, F., Zeng, Y., Zuo, S., Feng, S., Qi, C., Wang, B.-J., Yan, X.-J., Khademhosseini, A., et al. (2014) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1411295111 · Cited by 145
“The large dose of administered cells also poses higher risks of uncontrollable cell growth or even tumor genesis, especially when applying pluripotent stem cell-derived cells (13) or gene-transferred cells (14).”
Retracted
Cooperating cancer-gene identification through oncogenic-retrovirus–induced insertional mutagenesis
Du, Y., Spence, S. E., Jenkins, N. A., & Copeland, N. G. (2005) · Blood · doi:10.1182/blood-2004-12-4840 · Cited by 131
Novel Integrase-Defective Lentiviral Episomal Vectors for Gene Transfer
Vargas, J., Gusella, G. L., Najfeld, V., Klotman, M., & Cara, A. (2004) · Human Gene Therapy · doi:10.1089/104303404322959515 · Cited by 132
“ing stem cells transduced with an integrating retroviral vector as treatment for X-linked severe combined immunodeficiency disease (X-SCID) (Hacein-Bey-Abina et al., 2003).”
Performance- and safety-enhanced lentiviral vectors containing the human interferon-β scaffold attachment region and the chicken β-globin insulator
Ramezani, A., Hawley, T., & Hawley, R. (2003) · Blood · doi:10.1182/blood-2002-09-2991 · Cited by 143
Bcl-2 overexpression enhances tumor-specific T-cell survival.
Charo, J., Finkelstein, S., Grewal, N. S., Restifo, N., Robbins, P., & Rosenberg, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2006 · Cited by 142
“The development of leukemias in a recent clinical trial involving retrovirally transduced CD34+ cells highlights one of the risks posed by this cell modification approach (37).”
Background
Targeted homology-directed repair in blood stem and progenitor cells with CRISPR nanoformulations
Shahbazi, R., Sghia-Hughes, G., Reid, J. L., Kubek, S., Haworth, K. G., Humbert, O., Kiem, H., & Adair, J. E. (2019) · Nature Materials · doi:10.1038/s41563-019-0385-5 · Cited by 158
Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates
Schmidt, M., Carbonaro, D., Speckmann, C., Wissler, M., Bohnsack, J., Elder, M., Aronow, B., Nolta, J., Kohn, D., & von Kalle, C. (2003) · Nature Medicine · doi:10.1038/nm844 · Cited by 141
“Malignant transformation of T-cell clones containing a retroviral vector was recently observed in the clinical gene-transfer study for X-linked SCI”
BackgroundSelf-citation
Cationic lipid–DNA complexes for non-viral gene therapy: relating supramolecular structures to cellular pathways
Ewert, K., Ahmad, A., Evans, H. M., & Safinya, C. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.1.33 · Cited by 140
“In addition, a successful trial that used retroviral vectors to treat children with severe combined immunodeficiency [18] faced a major setback when two patients (out of ten) developed a leukaemia-like disease [19], later confirmed to have resulted from insertional mutagenesis [20].”
Background
Bromo- and Extraterminal Domain Chromatin Regulators Serve as Cofactors for Murine Leukemia Virus Integration
Gupta, S. S., Maetzig, T., Maertens, G. N., Sharif, A., Rothe, M., Weidner-Glunde, M., Galla, M., Schambach, A., Cherepanov, P., & Schulz, T. F. (2013) · Journal of Virology · doi:10.1128/jvi.01942-13 · Cited by 139
“To clone FLAG-tagged deletion constructs for MLV IN, IN fragments were PCR amplified from pQMLV-IN-FLAG plasmid using the following primer pairs: IN(110-409) ( NTD), SG1 and PC595; IN(160-409) ( CCD), SG2 and PC595; IN(1-278) ( CTD), PC594 and SG3; IN(160359) ( CCD CTD), SG2 and SG4.”
Method
Endosomal Escape Pathways for Non-Viral Nucleic Acid Delivery Systems
Liang, W., & Lam, J. K. W. (2012) · InTech eBooks · doi:10.5772/46006 · Cited by 137
Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial
Wang, G. P., Berry, C. C., Malani, N., Leboulch, P., Fischer, A., Hacein‐Bey‐Abina, S., Cavazzana, M., & Bushman, F. D. (2010) · Blood · doi:10.1182/blood-2009-12-257352 · Cited by 124
Self-citation
Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR
Cohen, C., Zheng, Z.-L., Bray, R., Zhao, Y.-B., Sherman, L., Rosenberg, S., & Morgan, R. (2005) · Journal of Immunology · doi:10.4049/jimmunol.175.9.5799 · Cited by 139
“The use of a single vector also decreases the potential for insertional mutagenesis (45).”
Background
Retroviral integration and human gene therapy
Bushman, F. D. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32949 · Cited by 138
GENE DELIVERY TO BONE
Evans, C. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.03.013 · Cited by 137
Retroviral gene therapy: safety issues and possible solutions.
Yi, Y., Hahm, S. H., & Lee, K.-H. (2005) · Current Gene Therapy · doi:10.2174/1566523052997514 · Cited by 137
Everything that Glitters Isn't Gold: A Critical Review of Postnatal Neural Precursor Analyses
Breunig, J. J., Arellano, J. I., Macklis, J. D., & RAKIC, P. T. (2007) · Cell stem cell · doi:10.1016/j.stem.2007.11.008 · Cited by 138
Sleeping Beauty Transposon‐Mediated Gene Therapy for Prolonged Expression
Hackett, P. B., Ekker, S. C., Largaespada, D. A., & McIvor, R. S. (2005) · Advances in genetics · doi:10.1016/s0065-2660(05)54009-4 · Cited by 140
Anti-Human Immunodeficiency Virus Hematopoietic Progenitor Cell-Delivered Ribozyme in a Phase I Study: Myeloid and Lymphoid Reconstitution in Human Immunodeficiency Virus Type-1–Infected Patients
Amado, R. G., Mitsuyasu, R. T., Rosenblatt, J. D., Ngok, F. K., Bakker, A., Cole, S. W., Chorn, N., Lin, L.-S., Bristol, G. C., Boyd, M. P., et al. (2004) · Human Gene Therapy · doi:10.1089/104303404322886101 · Cited by 139
Retroviral DNA integration: HIV and the role of LEDGF/p75.
Ciuffi, A., & Bushman, F. (2006) · Trends in Genetics · doi:10.1016/j.tig.2006.05.006 · Cited by 134
Retroviral DNA Integration—Mechanism and Consequences
Lewinski, M. K., & Bushman, F. D. (2005) · Advances in genetics · doi:10.1016/s0065-2660(05)55005-3 · Cited by 140
Molecular mechanisms of retroviral integration site selection
Kvaratskhelia, M., Sharma, A., Larue, R. C., Serrao, E., & Engelman, A. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku769 · Cited by 150
“In particular, MoMLV-based vectors have been successfully utilized in the treatment of primary immunodeficiencies (24,25).”
Method
Transfection efficiency boost of cholesterol-containing lipoplexes
Pozzi, D., Marchini, C., Cardarelli, F., Amenitsch, H. W., Garulli, C., Bifone, A., & Caracciolo, G. (2012) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2012.05.017 · Cited by 141
Retroviral Insertional Mutagenesis in Humans: Evidence for Four Genetic Mechanisms Promoting Expansion of Cell Clones
Bushman, F. D. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.009 · Cited by 160
Segmented poly(A) tails significantly reduce recombination of plasmid DNA without affecting mRNA translation efficiency or half-life
Trepotec, Z., Geiger, J., Plank, C., Aneja, M. K., & Rudolph, C. (2019) · RNA · doi:10.1261/rna.069286.118 · Cited by 129
“…gene therapy with DNA-based vectors, use of mRNA offers several advantages, such as transient expression (Kapeli and Yeo 2012; Lodish 2012), lack of necessity to enter the nucleus, and no risk of chromosomal integration (Cannon and Weissman 2002; Hacein-Bey-Abina et al. 2003; Bernal 2013).”
Background
Integrase-defective lentiviral vectors: Progress and applications
Banasik, M. B., & McCray, P. B. (2010) · Gene Therapy · doi:10.1038/gt.2009.135 · Cited by 129
In situ bone tissue engineering via ultrasound-mediated gene delivery to endogenous progenitor cells in mini-pigs
Bez, M., Sheyn, D., Tawackoli, W., Avalos, P., Shapiro, G., Giaconi, J., Da, X., David, S. B., Gavrity, J., Awad, H. A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3128 · Cited by 129
“In addition, clinical trials have shown that viral gene delivery can evoke a systemic inflammatory response resulting in death (32) and may cause carcinogenesis by random gene insertions into the genome (33, 34).”
Background
The role of the helper lipid dioleoylphosphatidylethanolamine (DOPE) for DNA transfection cooperating with a cationic lipid bearing ethylenediamine.
Mochizuki, S., Kanegae, N., Nishina, K., Kamikawa, Y., Koiwai, K., Masunaga, H., & Sakurai, K. (2013) · Biochimica et Biophysica Acta · doi:10.1016/j.bbamem.2012.10.017 · Cited by 129
Pluripotent stem cell-based therapy for Parkinson’s disease: Current status and future prospects
Sonntag, K., Song, B., Lee, N., Jung, J. H., Cha, Y., Leblanc, P. R., Neff, C., Kong, S. W., Carter, B. S., Schweitzer, J., et al. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.04.005 · Cited by 144
Intravenous Injection of a Lentiviral Vector Encoding NY-ESO-1 Induces an Effective CTL Response
Palmowski, M. J., Lopes, L. M., Ikeda, Y., Salio, M., Cerundolo, V., & Collins, M. K. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.3.1582 · Cited by 109
“Clearly, lentiviral vector safety will require rigorous testing before clinical trials, as there is potential for similar insertional mutagenesis to that seen with retroviral vectors (47).”
Background
Cell fusion: an alternative to stem cell plasticity and its therapeutic implications.
Vassilopoulos, G., & Russell, D. (2003) · Current Opinion in Genetics and Development · doi:10.1016/s0959-437x(03)00110-2 · Cited by 127
Enhancing and targeting nucleic acid delivery by magnetic force
Plank, C., Anton, M., Rudolph, C., Rosenecker, J., & Krötz, F. (2003) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.3.5.745 · Cited by 127
“This harbours substantial but difficult-to-assess risks including insertional mutagenesis [1].”
Background
New developments in lentiviral vector design, production and purification
Segura, M. M., Mangion, M., Gaillet, B., & Garnier, A. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.779249 · Cited by 127
“The main advantage of this strategy is to avoid the oncogene activation risk caused by random LVV insertion in the genome [72,73].”
Background
Retroviral Integrations in Gene Therapy Trials
Biasco, L., Baricordi, C., & Aiuti, A. (2012) · Molecular Therapy · doi:10.1038/mt.2011.289 · Cited by 106
A lentiviral vector encoding the human Wiskott–Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice
Charrier, S., Stockholm, D., Seye, K., Opolon, P., Taveau, M., Gross, D., Bucher-Laurent, S., Delenda, C., Vainchenker, W., Danos, O., et al. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302440 · Cited by 126
The role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion.
Nam, C.-H., & Rabbitts, T. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.010 · Cited by 126
A Phase I/II Clinical Trial of β‐Globin Gene Therapy for β‐Thalassemia
Bank, A., Dorazio, R., & Leboulch, P. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1345.007 · Cited by 125
Use of minicircle plasmids for gene therapy.
Mayrhofer, P., Schleef, M., & Jechlinger, W. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-561-9_4 · Cited by 125
Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations
Mendell, J. R., Connolly, A. M., Lehman, K. J., Griffin, D. A., Khan, S. Z., Dharia, S. D., Quintana-Gallardo, L., & Rodino-Klapac, L. R. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.02.011 · Cited by 124
Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review
Christodoulou, I., Goulielmaki, M., Devetzi, M., Panagiotidis, M., Koliakos, G., & Zoumpourlis, V. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-1078-8 · Cited by 122
“For example, AV expression is transient and often produces a significant host immune response, whereas RV may cause incorporation errors or even oncogene activation [283, 284].”
Background
Mutations in genes required for T-cell development:IL7R, CD45, IL2RG, JAK3, RAG1, RAG2, ARTEMIS, and ADA and severe combined immunodeficiency: HuGE review
Kalman, L. V., Lindegren, M. L., Kobrynski, L. J., Vogt, R. F., Hannon, H., Howard, J. T., & Buckley, R. H. (2004) · Genetics in Medicine · doi:10.1097/01.gim.0000105752.80592.a3 · Cited by 133
Estimating abundances of retroviral insertion sites from DNA fragment length data
Berry, C. C., Gillet, N. A., Melamed, A., Gormley, N. A., Bangham, C. R. M., & Bushman, F. D. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts004 · Cited by 134
Scavenger Receptors and Their Potential as Therapeutic Targets in the Treatment of Cardiovascular Disease
Stephen, S. L., Freestone, K., Dunn, S., Twigg, M. W., Homer‐Vanniasinkam, S., Walker, J. H., Wheatcroft, S. B., & Ponnambalam, S. (2010) · International Journal of Hypertension · doi:10.4061/2010/646929 · Cited by 97
“Two different gene therapy studies on X-linked SCID (SCID-X1) using retroviral vector integration resulted in leukemia induction in four out of nine subjects with one death [165, 166] and leukemia in one out of ten subjects [167, 168].”
Background
Comparison of HIV-derived Lentiviral and MLV-based Gammaretroviral Vector Integration Sites in Primate Repopulating Cells
Beard, B. C., Dickerson, D. R., Beebe, K., Gooch, C., Fletcher, J., Okbinoglu, T., Miller, D. G., Jacobs, M. A., Kaul, R., Kiem, H., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300159 · Cited by 121
Review of gene therapies for age-related macular degeneration
Khanani, A. M., Thomas, M. J., Aziz, A. A., Weng, C. Y., Danzig, C. J., Yiu, G., Kiss, S., Waheed, N. K., & Kaiser, P. K. (2022) · Eye · doi:10.1038/s41433-021-01842-1 · Cited by 119
“In 1999, gene therapy for the treatment of severe combined immunodeficiency-X1 ultimately resulted in the death of one patient from unforeseen oncogene activation [4].”
Background
Genome-Wide Mapping of PiggyBac Transposon Integrations in Primary Human T Cells
Galvan, D. L., Nakazawa, Y., Kaja, A., Kettlun, C. S., Cooper, L., Rooney, C., & Wilson, M. H. (2009) · Journal of immunotherapy · doi:10.1097/cji.0b013e3181b2914c · Cited by 119
Integration Site Preference of Xenotropic Murine Leukemia Virus-Related Virus, a New Human Retrovirus Associated with Prostate Cancer
Kim, S., Kim, N., Dong, B., Boren, D., Lee, S. A., Gupta, J. D., Gaughan, C., Klein, E. A., Lee, C. S., Silverman, R. H., et al. (2008) · Journal of Virology · doi:10.1128/jvi.01299-08 · Cited by 106
“This concern is poignantly demonstrated by the subsequent development of leukemia in three children with X-linked severe combined immunodeficiency after an otherwise successful gene therapy trial by use of an MLV-derived vector (36, 37).”
Background
Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients
Marcucci, K. T., Jadlowsky, J. K., Hwang, W., Suhoski, M. M., Gonzalez, V. E., Kulikovskaya, I. M., Gupta, M., Lacey, S. F., Plesa, G., Chew, A., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.012 · Cited by 137
SIN Retroviral Vectors Expressing COL7A1 Under Human Promoters for Ex Vivo Gene Therapy of Recessive Dystrophic Epidermolysis Bullosa
Titeux, M., Pendaries, V., Zanta, M. A., Décha, A., Pironon, N., Tonasso‐Calvière, L., Mejía, J. E., Brice, A., Danos, O., & Hovnanian, A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.91 · Cited by 114
Novel vectors and approaches for gene therapy in liver diseases
Maestro, S., Weber, N. D., Zabaleta, N., Aldabe, R., & González‐Aseguinolaza, G. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100300 · Cited by 143

Authors: Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., & Fischer, A.
ORCID: Schmidt, Manfred
Villeval, Jean-Luc
Fischer, Alain
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2003-01-16
Volume: 348
Issue: 3
Pages: 255-256
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm200301163480314
OpenAlex: W2323613689
Cited by: 1,867
References: 0
Citations by year: 2026: 29 · 2025: 32 · 2024: 31 · 2023: 25 · 2022: 47 · 2021: 52 · 2020: 46 · 2019: 50 · 2018: 45 · 2017: 63 · 2016: 65 · 2015: 84 · 2014: 87 · 2013: 92 · 2012: 92
FWCI: 86.98
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
DigitalGeorgetown (Georgetown University Library) (submittedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Keywords: X-linked severe combined immunodeficiency, gene therapy, adverse events, gene therapy safety
MeSH terms: Chromosomes, Human, Pair 11, DNA-Binding Proteins, Humans, Genetic Linkage, Metalloproteins, Proto-Oncogene Proteins, Retroviridae, Genetic Therapy, Gene Expression, Mutagenesis, Insertional, Severe Combined Immunodeficiency, Lymphocyte Count, Chromosomes, Human, X, Adaptor Proteins, Signal Transducing, Precursor Cell Lymphoblastic Leukemia-Lymphoma, LIM Domain Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Metadata

Record

About these checks